Novo Nordisk

Novo Nordisk has officially introduced its blockbuster diabetes drug Ozempic to the Indian market, a move that could significantly reshape treatment options for Type 2 diabetes. Widely prescribed globally, Ozempic belongs to the GLP-1 receptor agonist class and is known for improving blood sugar control while supporting weight management. Its entry into India comes amid rising diabetes prevalence and growing demand for advanced therapies.

In a significant step toward combating India's growing obesity epidemic, Danish pharmaceutical major Novo Nordisk has launched its globally acclaimed anti-obesity drug Wegovy in India. The drug, which contains semaglutide as its active ingredient, is indicated for chronic weight management and the reduction of major cardiovascular risks in overweight and obese adults. Offered in five dose strengths through a once-weekly injectable pen device, Wegovy is priced between Rs. 17,345 and Rs. 26,050 per month.